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Introduction: The purpose of the present study was to assess the prevalence and determinants 
of menstrual cycle disorders among women with epilepsy.
Materials and methods: The study included consecutive women with epilepsy who visited 
a university epilepsy clinic. A number of variables, including demographics, characteristics of 
epilepsy and its treatment, and data related to reproductive health (regularity of menstrual cycle, 
number of pregnancies and childbirths), were collected from medical records, seizure diaries, 
and a dedicated questionnaire.
Results: The study involved 271 women with epilepsy. Focal epilepsy was diagnosed in 
182 (67.2%) patients; 108 (39.8%) women had rare seizures (,1 per year), and 164 patients 
(60.5%) were on monotherapy. Menstrual abnormalities were found in 78 patients (28.8%). 
Independent variables associated with irregular cycle included younger age at onset of epilepsy 
(OR=0.95 per 1-year increase; P=0.008), current use of clonazepam (OR=5.36; P=0.010), and 
chronic use of medication(s) other than antiepileptic drug(s) (AEDs; OR=2.48; P=0.003). 
Childbirth rate was low in our cohort (0.50 per patient); independent predictors of being childless 
in studied patients included younger age, presence of menstrual disorders, and greater number 
of currently used AEDs.
Conclusion: Menstrual disturbances were present in 28.8% of studied women with epilepsy. 
Increased prevalence of menstrual abnormalities was associated with epilepsy itself (younger 
age at onset of epilepsy) and its treatment (ongoing use of clonazepam), as well as with chronic 
use of medications other than AEDs.
Keywords: menstrual disorders, medications, side effect, women, reproductive health
Introduction
Reproductive health-related issues are among the most important considerations in 
women with epilepsy, especially in those treated and followed up for many years since 
the onset of the disease. Menstrual abnormalities, including irregular menstrual cycle, 
oligo-, poly-, or amenorrhea, are reported more often in women with epilepsy than in 
the general population.1 The potential causes are likely multifactorial but most con-
sistently include frequent seizures1 and the use of specific antiepileptic drugs (AEDs), 
that is, valproic acid (VPA)1 or carbamazepine2 and the need for polytherapy.1 On the 
other hand, the rate of menstrual abnormalities was similar regardless of epilepsy type 
(localization related vs idiopathic generalized epilepsy).1,3,4
Although management of pregnant women with epilepsy, teratogenicity of AEDs, 
and outcome of pregnancy in this subgroup of patients are all well described, the issue 
of menstrual abnormalities is relatively less known and most data come from several 
studies performed more than a decade ago.1–7 Gaps in evidence are related to the intro-
duction of new AEDs and relative paucity of information related to association between 
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menstrual disturbances and factors other than epilepsy or 
its treatment. Thus, we would like to establish whether any 
AED (especially newer ones) affects the occurrence of the 
menstrual irregularities. We were also interested if there was 
any additional impact of nonneurological comorbidities or 
chronically used medications, as the prevalence of menstrual 
abnormalities in general population is influenced by smoking, 
obesity, and chronic stress.8
The purpose of the present study was therefore to assess 
the prevalence and determinants of menstrual cycle disorders 
among Polish women with epilepsy.
Materials and methods
Patients
This study included consecutive female patients with epilepsy 
who visited the tertiary outpatient epilepsy clinic at the 
Department of Neurology within University Hospital in 
Kraków between January 2016 and October 2017. Inclusion 
criteria comprised female sex and the diagnosis of epilepsy 
according to the International League Against Epilepsy 
guidelines and classifications.9–11 Exclusion criteria com-
prised pregnancy, current use of steroid hormones (including 
oral contraceptives), active malignancy, or recent (ie, within 
6 months) change of AED(s) used to treat epilepsy. We have 
also excluded women after menopause.
Protocol of the study complied with principles of Helsinki 
Declaration and received approval from bioethical committee 
of the Jagiellonian University of Kraków. Each patient was 
informed about the aim and methods of the study, and they 
gave the written informed consent to participate.
Methods
The study had a cross-sectional design. Data were collected 
from patients’ medical records, containing comprehensive 
history, results of neurological examination, and results of 
diagnostic studies.
Each patient treated in our outpatient clinic is required to 
keep the personal seizure diary with prospective collection of 
data regarding seizures and medication(s). For the purpose 
of this particular study, patients were additionally asked 
to prospectively record the date of the first day of menses 
and duration of their menstrual period during consecutive 
6 months. The raw data were then retrieved and stored in 
the electronic form during the visit scheduled 6–8 months 
after the baseline one.
Variables related to epilepsy included age at the diagnosis 
of epilepsy and the type of epilepsy established accord-
ing to the data from history, neurological examination, 
electroencephalography, and neuroimaging (MRI or com-
puted tomography if MRI was contraindicated). The type of 
epilepsy was retrospectively classified with the terminology 
used in a recent International League Against Epilepsy posi-
tion paper on classification of epilepsies (generalized, focal, 
combined generalized and focal, or unknown) to facilitate 
future comparisons.12 The onset of epilepsy was defined as 
the occurrence of the first-ever seizure. Frequency of seizures 
within the year preceding the ongoing visit was established 
according to the data included in the seizure diaries and cat-
egorized into 1) more than one seizure per month; 2) 1–12 
seizures per year; or 3) less than one seizure per year (the last 
one considered as “rare seizures”). The type, number, and 
daily dose of AED(s) used at the time of the assessment were 
noted. The number of previously used AEDs was also noted.
The questionnaire dedicated for this study included ques-
tions related to the reproductive health issues. We have noted 
the age at the menarche and whether the onset of epilepsy 
preceded the menarche (by recall). The numbers of preg-
nancies, births (including vaginal deliveries and cesarean 
sections), and children were recorded as well.
Menses were considered irregular, if any of the follow-
ing abnormalities occurred at least once during the 6-month 
follow-up: irregular cycle (cycle length varying more than 
4 days from cycle to cycle), oligomenorrhea (cycle length 
longer than 35 days), polymenorrhea (cycle length shorter 
than 22 days), or amenorrhea (no menstrual bleeding during 
6 months of follow-up).
Using the medical records and interview, we have 
obtained information on concomitant chronic disorders active 
at the moment of the assessment. They were classified as 
heart disorders, diabetes, allergies, gastrointestinal diseases, 
hypercholesterolemia, endocrine or psychiatric disorders. 
We have also noted the chronic daily use of any medication 
unrelated to the management of epilepsy.
statistical analysis
Descriptive statistics used numbers and percentages for 
qualitative variables, as well as means with SD or medians 
with interquartile ranges for quantitative variables. Chi-
squared test (or Fisher’s exact test, where appropriate) was 
used to assess the significance of the differences between 
the qualitative data. Student’s t-test was used to assess dif-
ferences between quantitative variables.
Univariate analysis included comparison of recorded 
variables between groups of patients with regular and 
irregular menses as well as between patients with and with-
out children.
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Analyses of independent factors that influenced occur-
rence of irregular menses or having children (dependent 
variables) were performed by logistic regression modeling. 
Initial models were built with all the variables that differed 
at the level of P,0.1 in univariate analysis. Models were 
created using stepwise method (backward selection with 
determining criterion likelihood ratio for variables selection). 
A P-value ,0.05 was considered statistically significant for 
the differences between groups or for variables that entered 
the final models of logistic regression. All the analyses were 
performed using Statistica v. 12.5 (StatSoft Inc., Tulsa, 
OK, USA).
Results
The study involved 271 women aged between 18 and 49 years 
who visited the tertiary outpatient epilepsy clinic between 
January 2016 and October 2017. All patients who fulfilled 
inclusion criteria and had no exclusion criterion agreed to 
participate.
Table 1 provides data related to the age of participants, 
age at the diagnosis of epilepsy, type(s) of seizures, fre-
quency of seizures, the most commonly used AEDs as well 
as co-occurrence of other chronic diseases and the chronic 
use of medications other than AEDs.
At the time of the assessment, all patients were treated 
with at least one AED; 164 patients (60.5%) were on mono-
therapy. Polytherapy with two AEDs was used by 77 patients 
(28.4%); 26 patients (9.6%) were treated with three AEDs 
and other 4 (1.5%) used four AEDs. The following AEDs 
(in alphabetical order) were used at the time of assessment at 
least by one patient: carbamazepine, clobazam, clonazepam, 
ethosuximide, gabapentin, lacosamide, lamotrigine, leveti-
racetam, oxcarbazepine, phenobarbital, phenytoin, primi-
done, tiagabine, topiramate, valproate, and vigabatrin.
Data on reproductive health-related measures, including 
age at menarche, age at menopause, prevalence of menstrual 
abnormalities, as well as numbers of pregnancies and children 
are shown in Table 2. Menstrual abnormalities, in general, 
were found in 78 out of the 271 studied patients (28.8%). 
Two patients had primary amenorrhea due to Rokitansky–
Meyer syndrome and other two had primary amenorrhea 
because of unknown reason. There were 167 pregnancies in 
271 patients (0.62 per patient) and 136 children were born to 
those women (0.50 per patient). Majority of patients (n=186, 
68.6%) had no children.
Table 3 shows the differences between women with 
and without menstrual abnormalities. When compared 
with women without menstrual abnormalities, those with 
abnormal menstruation were slightly younger at the time of 
Table 1 general characteristics of studied women with epilepsy
Variable N=271
age (years); mean (sD)
age at onset of epilepsy (years); mean (sD)
epilepsy type
generalized
Focal
combined (generalized and focal)
Unknown
Frequency of seizures
.1 per month
1–12 per year
,1 per year
The most commonly used aeDs (in mono- 
or polytherapy)
Valproate
levetiracetam
lamotrigine
carbamazepine
Topiramate
Oxcarbazepine
clonazepam
concomitant disorders
allergies
gastrointestinal disorders
endocrine disorders
Psychiatric disorders
any concomitant disorder
chronic use of medications other than aeD
29.6 (7.3)
14.5 (8.5)
74 (27.3%)
182 (67.2%)
6 (2.2%)
9 (3.3%)
101 (37.3%)
62 (22.9%)
108 (39.8%)
108 (39.9%)
95 (35.1%)
73 (26.9%)
48 (17.7%)
31 (11.4%)
26 (9.6%)
13 (4.8%)
23 (8.5%)
8 (3.0%)
32 (11.8%)
33 (12.2%)
91 (33.6%)
78 (28.9%)
Abbreviation: aeD, antiepileptic drug.
Table 2 reproductive health-related measures among studied 
patients with epilepsy
Variable N=271
age at menarche (years); mean (sD)
Onset of epilepsy before the menarche
Menstrual abnormalities
Polymenorrhea (,21 days)
Oligomenorrhea (.35 days)
amenorrhea
Number of patients with given number of pregnancies
0
1
2
3
4
5
Number of patients with given number of children
0
1
2
3
Vaginal deliveries
cesarean sections
13.2 (1.7)
104 (38.5%)
78 (28.8%)
0
6 (2.3%)
4 (1.5%)
181 (66.8%)
39 (14.4%)
33 (12.2%)
11 (4.0%)
6 (2.2%)
1 (0.4%)
186 (68.6%)
42 (15.5%)
35 (12.9%)
8 (3.0%)
74
67
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the assessment and were younger at the onset of epilepsy. 
Patients with irregular menstrual cycle were more likely to 
have the onset of epilepsy before menarche; they were also 
younger when menarche occurred. No difference between 
those two groups was found regarding the prevalence of 
specific concomitant disorders but women with menstrual 
abnormalities were more likely to have one of the recorded 
concomitant disorder and were more likely to chronically 
use medication(s) other than AEDs. Patients with irregular 
menstrual cycle used clonazepam more frequently than their 
counterparts with regular cycle and were less likely to have 
rare seizures (less than one per year). Otherwise, no specific 
medication or use of monotherapy or polytherapy differenti-
ated those two groups.
Table 3 comparison of demographic features, characteristics of the epilepsy, and antiepileptic medications between patients with 
regular and irregular menstrual cycle among studied patients with epilepsy
Variable Patients with menstrual 
abnormalities
(n=78)
Patients without menstrual 
abnormalities 
(n=193)
P-value
age (years); mean (sD)
age at onset of epilepsy (years); mean (sD)
age at menarche (years); mean (sD)
Onset of epilepsy before the menarche
epilepsy type
generalized
Focal
combined (generalized and focal)
Unknown
Frequency of seizures
.1 per month
1–12 per year
,1 per year
concomitant disorders
heart diseases
Diabetes
allergies
gastrointestinal disorders
hypercholesterolemia
endocrine disorders
Psychiatric disorders
any concomitant disorder
chronic use of medications other than aeD
Number of currently used aeDs
Monotherapy
Two drugs
Three drugs
Four drugs
currently used aeDs
Valproic acid
lamotrigine
levetiracetam
ethosuximide
Topiramate
clonazepam
Phenobarbital
carbamazepine
Oxcarbazepine
Tiagabine
Phenytoin
gabapentin
Vigabatrin
lacosamide
Primidone
clobazam
28.2 (6.6)
11.6 (7.5)
12.9 (1.6)
40 (51.9%)
17 (21.8%)
53 (67.9%)
6 (7.7%)
2 (2.6%)
35 (44.9%)
20 (25.6%)
23 (29.5%)
2 (2.6%)
1 (1.3%)
9 (11.5%)
4 (5.1%)
1 (1.3%)
11 (14.1%)
12 (15.4%)
34 (43.6%)
31 (39.7%)
46 (59.0%)
20 (25.6%)
9 (11.5%)
3 (3.8%)
36 (46.1%)
25 (32.0%)
24 (30.8%)
0
9 (11.5%)
9 (11.5%)
0
12 (15.4%)
8 (10.2%)
1 (1.3%)
0
0
2 (2.6%)
2 (2.6%)
0
3 (3.8%)
30.1 (7.5)
15.6 (8.6)
13.3 (1.7)
64 (33.2%)
57 (29.5%)
129 (66.8%)
0
7 (3.6%)
66 (34.2%)
42 (21.8%)
85 (44.0%)
6 (3.1%)
0
14 (7.2%)
4 (2.1%)
0
21 (10.9%)
21 (10.9%)
57 (29.5%)
47 (24.5%)
118 (61.1%)
57 (29.5%)
17 (8.8%)
1 (0.5%)
72 (37.3%)
48 (24.9%)
71 (36.8%)
4 (2.1%)
22 (11.4%)
4 (2.1%)
2 (1.0%)
36 (18.6%)
18 (9.3%)
1 (0.5%)
1 (0.5%)
3 (1.5%)
0
4 (2.1%)
1 (0.5%)
3 (1.5%)
0.051
,0.001
0.06
0.006
0.19
0.86
,0.001
0.49
0.10
0.49
0.03
0.58
0.29
0.25
0.17
0.29
0.46
0.30
0.03
0.01
0.74
0.52
0.49
0.07
0.18
0.23
0.35
0.51
0.97
0.002
0.51
0.52
0.81
0.49
0.71
0.36
0.08
0.55
0.71
0.23
Abbreviation: aeD, antiepileptic drug.
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Table 4 shows comparison of women with epilepsy 
who have or do not have children. Childless patients were 
younger at the time of assessment and at the time of epilepsy 
onset. They were less likely to have regular menstrual cycle 
as well and more often had onset of epilepsy before their 
menarche.
Multivariate analysis revealed three independent vari-
ables associated with menstrual abnormalities, ie, younger 
age at onset of epilepsy, current use of clonazepam, and 
chronic use of medication(s) other than AEDs (see Table 5 
for details).
Multivariate analysis of variables associated with 
having children revealed three independent predictors, that 
is, younger age, smaller number of currently used AEDs, 
and lacking menstrual cycle abnormalities (see Table 6 for 
details).
Discussion
The study revealed the presence of menstrual abnormalities in 
more than one-fourth of studied Polish women with epilepsy. 
We have also shown that not only epilepsy or its treatment but 
also concomitant nonneurological disorders (or, alternatively, 
chronic use of medications other than AEDs) are associated 
with increased prevalence of menstrual irregularity in this 
cohort of patients.
Prevalence of menstrual abnormalities among women 
with epilepsy in previously published studies is quite diver-
gent. The methodological factors affecting its values include 
population studied and definition of menstrual irregular-
ity, among others. Most studies on this topic involved 
selected patients with either focal6,13,14 or primary general-
ized epilepsy.5 They comprised at most 100 patients and 
revealed presence of menstrual abnormalities in 20%–33.3% 
of subjects. Several studies that used unselected samples 
of women with various types of epilepsy were published 
in 1990s or early 2000s. Isojärvi et al15 found menstrual 
abnormalities in 20% of 238 women with various types of 
epilepsy seen in an outpatient clinic. A similar rate (19.6% of 
women with irregular menstruation and/or hirsutism among 
472 evaluated patients) was found in a most recent Indian 
study.4 Murialdo et al3 noted menstrual abnormalities (defined 
as a secondary amenorrhea, oligo- or polymenorrhea) in 
Table 4 comparison of women with and without children among studied patients with epilepsy
Variable Patients who have  
children
(n=85)
Patients who do not  
have children
(n=186)
P-value
age (years); mean (sD)
age at onset of epilepsy (years); mean (sD)
age at menarche (years); mean (sD)
Onset of epilepsy before the menarche
Menstrual abnormalities
epilepsy type
generalized
Focal
combined (generalized and focal)
Unknown
Frequency of seizures
.1 per month
1–12 per year
,1 per year
Monotherapy
35.6 (6.3)
17.6 (9.9)
13.3 (1.6)
25 (29.8%)
14 (16.5%)
18 (21.2%)
63 (74.1%)
0
4 (4.7%)
33 (38.8%)
21 (24.7%)
31 (36.5%)
45 (52.9%)
26.8 (6.0)
13.0 (7.4)
13.1 (1.7)
79 (42.5%)
64 (34.4%)
56 (30.1%)
119 (64.0%)
6 (3.2%)
5 (2.7%)
68 (36.6%)
41 (22.0%)
77 (41.4%)
119 (64.0%)
,0.001
,0.001
0.38
0.04
0.002
0.13
0.10
0.10
0.30
0.72
0.63
0.15
0.08
Table 5 independent factors associated with menstrual abnormalities in studied women with epilepsy
Variablesa Standard error Wald statistics P-value OR (95% CI)
chronic use of medication(s) other than aeDb
age at onset of epilepsyc
current use of clonazepam
0.30
0.02
0.65
8.75
7.18
6.58
0.003
0.008
0.010
2.48 (1.35–4.53)
0.95 (0.91–0.99)
5.36 (1.48–19.45)
Notes: χ2 test=29.9; P,0.001. aThe following variables were subsequently removed from the model with the backward elimination procedure: current use of vigabatrin 
(P=0.66), age at menarche (P=0.59), onset of epilepsy before menarche (P=0.90), number of aeDs in current use (P=0.33), type of epilepsy (P=0.30), frequency of seizures 
(P=0.18), and age (P=0.11). bWhen “chronic use of medication(s) other than aeD” was replaced by the “presence of any chronic disorder”, the latter one was also an 
independent predictor of menstrual abnormalities (P=0.005; Or: 2.30, 95% ci: 1.28–4.14). cOr per 1-year increase.
Abbreviation: aeD, antiepileptic drug.
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
18
5.
17
2.
86
.1
91
 o
n 
06
-M
ay
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2018:14submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2662
Bosak et al
21.8% out of 101 women with epilepsy. Higher rates of men-
strual irregularities were reported in two other Scandinavian 
studies – Löfgren et al7 found them in 35% of women with 
epilepsy and Svalheim et al noted such abnormalities even 
in 48% of patients (compared with very high rate of 30.7% 
among controls).1 The rate of women with menstrual abnor-
malities in our study (28.8%) is therefore in the middle of 
the range found in the previous studies.
We did not use a case–control design, so it is impossible 
to state clearly that the rate of irregular cycles found in our 
study is higher than that seen among women without epilepsy. 
However, in majority of studies that included control groups, 
rates of women with irregular menses were significantly 
higher among patients with epilepsy.1,14
Independent factors associated with irregular menstrua-
tion among studied women with epilepsy included younger 
age at onset of epilepsy, treatment with clonazepam, and 
presence of concomitant nonneurological chronic diseases.
Younger age at onset of epilepsy as a predictor of 
menstrual abnormalities is most probably related to the 
early impact of either epilepsy itself or its treatment on the 
complex neuroendocrine regulation of menstrual cycle as 
reviewed recently by Pennel.16 According to Herzog et al,14 
both interictal epileptiform discharges and use of enzyme-
inducing AED lead to alterations of hypothalamo pituitary 
regulation of gonadal secretion. We can only speculate that 
the early onset of epilepsy might affect the development of 
normal functioning of hypothalamopituitary-gonadal axis at 
the most vulnerable moment. In line with this, we have also 
noted greater prevalence of menstrual disorders in patients 
with the onset of epilepsy preceding menarche (in univariate 
analysis only). On the other hand, Svalheim et al1 did not 
observe any association between age at onset (or duration 
of epilepsy) and rate of menstrual disorders among women 
with epilepsy evaluated in population-based study.
Clonazepam is an AED rarely used in chronic man-
agement of epilepsy. In our institution, it is used to treat 
some patients with drug-resistant epilepsy. To the best 
of our knowledge, there are no data that may suggest the 
pathomechanistic association between the chronic use of 
benzodiazepines (including clonazepam) and subsequent 
menstrual abnormalities. In our opinion, it is more likely that 
the use of clonazepam in our cohort was a marker of more 
severe epilepsy in general and this characteristic might influ-
ence the greater prevalence of menstrual disorders in women 
taking clonazepam. On the other hand, neither frequent 
seizures nor number of AEDs could substitute treatment 
with clonazepam in multivariable logistic regression model. 
It may suggest some importance of clonazepam outside its 
association with more severe epilepsy.
It is widely known that the use of VPA is a widely accepted 
risk factor for hyperandrogenism, polycystic ovarian syn-
drome, and anovulation among women with epilepsy15,17 
but contrary to some previous studies,1 we did not find an 
independent role of VPA as a medication causing menstrual 
disorders.
The study somehow provided reassuring findings related 
to the use of newer AEDs and risk of menstrual abnormali-
ties. We did not note any significant difference in the rate of 
irregular menstruation among patients who used lamotrigine, 
levetiracetam, lacosamide, or topiramate. It is worthy to note 
that most of the previous studies did not report patients using 
topiramate, levetiracetam, or lacosamide because they had 
been published before any meaningful experience with those 
AEDs was accumulated.
Childbirth rates are thought to be lower among women 
with epilepsy than in general population18,19 but this notion 
was challenged in some other population-based studies.20,21 
We did not use a case–control design. Thus, we can only 
compare the parity calculated for the studied population with 
the parity in Polish population which was 1.29 in 2015.22 
Of note, two out of three independent factors associated with 
being childless in our sample (younger age and irregularity of 
menstrual cycle) were not related directly to the epilepsy itself. 
Women in Poland tend to postpone the decision on conception 
to older age (median age at the first childbirth was 22.7 in 
1990, 23.7 in 2000, and 27.6 in 2015),22 which might be the 
reason for smaller parity among studied patients with epilepsy 
in whom young women were quite prevalent. The third inde-
pendent variable – the number of currently used AEDs – may 
Table 6 independent factors associated with having children in studied women with epilepsy
Variablesa Standard error Wald statistics P-value OR (95% CI)
ageb
Menstrual abnormalities
Number of currently used aeDs
0.03
0.39
0.25
58.9
3.93
3.93
,0.001
0.047
0.047
1.24 (1.18–1.32)
0.46 (0.21–0.99)
0.61 (0.38–0.99)
Notes: χ2 test=101.9; P,0.001. aThe following variables were subsequently removed from the model with the backward elimination procedure: onset of epilepsy before 
menarche (P=0.73), type of epilepsy (P=0.51), frequency of seizures (P=0.51), and age at onset of epilepsy (P=0.29). bOr per 1-year increase.
Abbreviation: aeD, antiepileptic drug.
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be viewed as the marker of more severe epilepsy with all its 
consequences, including individual decisions driven by the 
patients’ concerns about outcome of pregnancy and perceived 
risks for the well-being of a child. In line with this explanation, 
it was shown previously that one-third of women affected 
with epilepsy did not consider having children because of 
their epilepsy.23 Taken together, these factors along with the 
irregular menstruation might partially explain the relatively 
low childbirth rates among Polish patients with epilepsy but 
this notion should be considered as very preliminary because 
our study was not a population-based one.
We acknowledge several limitations related to our findings 
and their interpretation. First, the cohort of studied patients 
involved women followed up in tertiary epilepsy clinic and 
may be not representative of general population of female 
patients with epilepsy. It should be noted, however, that we 
have included consecutive patients with epilepsy without 
exclusions related to any of the characteristics of the disease. 
Our primary goal was to evaluate the prevalence of menstrual 
disorders among largely unselected group of patients with 
epilepsy. Consequently, our exclusion criteria were minimal 
and did not include specific causes of those abnormalities. We 
did not perform formal gynecological and endocrinological 
assessments; so, the relative contribution of endometriosis 
of polycystic ovary syndrome, known to be associated with 
dysmenorrhea,24,25 could not be established in the present 
study. In our opinion, the disentanglement of the complex 
associations between epilepsy, its treatment, polycystic ovary 
syndrome, and menstrual abnormality might be extremely 
difficult, as those relations are likely multidirectional.
Second, our study did not comprise the control group. 
Thirdly, the definition of “other chronic diseases” was rather 
general and might be viewed as too simplistic but the propor-
tion of patients who chronically used any medications unre-
lated to their epilepsy was considered as fair approximation 
of the importance of their chronic diseases. As expected, it 
was similar to the proportion of the patients with concomitant 
disorders and, indeed, did similarly well when put into the 
model of independent predictors instead of “any concomitant 
disorder” (see Table 5).
Our results stress the importance of other, nonneurological 
disorders (or their treatment) as the predictor of menstrual 
abnormalities; it is suggested that the use of medications 
other than AED or presence of chronic disorders other than 
epilepsy should be included in the differential diagnosis of 
potential causes of menstrual disorders. It is our impression 
that the occurrence of menstrual abnormalities in women with 
epilepsy treated with AED is too often attributed to epilepsy 
or its treatment without broader assessment of other causes. 
Meanwhile, some lifestyle-related problems, for example, 
obesity, seem to affect the prevalence of menstrual disorders. 
As reviewed recently by Seif et al26 obesity itself is associated 
with the increased frequency of menstrual disorders due to 
several hormonal abnormalities (ie, increased concentrations 
of testosterone and lower concentrations of sex hormone-
binding globulin, as well as increased frequency of luteiniz-
ing hormone pulses). We did not calculate body mass index 
or other measures of obesity, so it is impossible to draw direct 
conclusions about the significance of obesity as a potential 
risk factor for menstrual abnormalities in our cohort. Given 
the potential importance of this association, the future studies 
should evaluate these relationships in details.
The association between epilepsy and menstrual disorders 
is also likely to be bidirectional. Although our study focused 
on the prevalence of menstrual abnormalities and we did not 
assess the level of sex hormones throughout the cycle, it is 
worthy to point to the plausible relation of anovulatory cycles 
with the increased frequency of generalized tonic-clonic 
seizures in women serving as their own controls.27 Thus, it 
may occur that the menstrual abnormalities (specifically, 
anovulation) due to factors unrelated to epilepsy itself might 
affect the severity of epilepsy, leading to confusion between 
cause and effect.
Irregular menstrual cycle might have a potential sig-
nificance beyond the traditional association with decreased 
fertility or neuroendocrine abnormalities secondary to 
epilepsy or its treatment. For example, it may independently 
increase the risk of coronary heart disease which was shown 
in a prospective study.28 Thus, the information on repro-
ductive health-related issues should be a part of a routine 
assessment in women with epilepsy. The increased awareness 
of the presence of menstrual abnormalities among women 
with epilepsy might be the first step toward the interven-
tion, for example, modification of treatment. It was shown 
recently that the menstrual disturbances noted in women who 
initially used VPA are reversible when VPA is switched to 
lamotrigine.29 Future studies should bring more unequivocal 
findings related to the potential interventions that might 
improve quality of life among women with epilepsy who 
suffer from menstrual irregularity and its consequences.
Conclusion
Menstrual disturbances were present in 28.8% of studied 
women with epilepsy. Increased prevalence of menstrual 
abnormalities was associated with epilepsy itself (younger 
age at onset of epilepsy) and its treatment (ongoing use of 
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clonazepam), as well as with chronic use of medications 
other than AEDs.
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